ROLE OF MYO-INOSITOL SUPPLEMENTATION IN PREVENTION OF GESTATIONAL DIABETES MELLITUS IN PARTURIENT WOMEN AT RISK

Abstract

Objective: To evaluate the incidence of gestational diabetes mellitus (GDM) among pregnant women at risk following the administration of Myo-Inositol in comparison to a placebo.

Study design: A randomized controlled trial

Place and Duration This study was conducted in Bolan Medical Complex Hospital Quetta from September 2022 to September 2023.

Methodology: Regardless of parity, a total of 100 pregnant women in the first trimester who had  at least one first-degree relative with diabetes mellitus and who were overweight (BMI >25 kg/m2) or obese (BMI >30 kg/m2) at their first prenatal visit were participated. The women who met the exclusion criteria had already been diagnosed with diabetes mellitus. The intervention group got a daily dosage of 2g Myo-Inositol and 200 mcg Folic acid starting from the end of the first trimester or the beginning of the second trimester (12–15 weeks of gestation), while the placebo group only received 200 mcg Folic acid twice daily. Every subject was tested for a 75gm 2-hour OGTT between 24 and 48 weeks.

Results: The mean age of the female participants in the intervention group was 27.45 ± 4.28 years, whereas it was 28.77 ± 4.26 years in the placebo group. The mean gestational age of the intervention group was 9.26 ± 1.89 weeks, whereas the mean gestational age of the placebo group was 9.48 ± 1.79 weeks. The study found that among at-risk parturient women using myo-inositol-containing supplements, the incidence of gestational diabetes mellitus was 17%, while in the placebo group, it was 37% (p-value, 0.01).

Conclusion: Supplementing with myo-inositol has been shown to lower the incidence of gestational diabetes mellitus in pregnant women who have been recognized as having risk factors.